Session 21 of FOPE, PharmaState Academy’s PULSE Program, advances excellence in manufacture of APIs…
The keynote address was given by Namit Joshi, Chairman, Pharmexcil, followed by the expert educator session by Dr Jitender…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
FOPE, PharmaState Academy’s 16th PULSE Session held on Oral Liquids manufacturing under Revised…
The session opened with a keynote address by Dr Viranchi Shah, followed by an education segment led by Abhijit S. Kulkarni, VP CQA…
BD announces first pharma-sponsored clinical trial using BD Libertas wearable injector technology…
The BD Libertas Wearable Injector is a prefilled, patient ready-to-use drug delivery system designed to enable delivery of complex…
NATCO Pharma offers to acquire stake in South African Adcock Ingram Holdings
Adcock Ingram generated revenue of R9.6 billion ($ 536 million*) in the financial year June’24 and delivered a gross margin of…
48 Projects approved under the PLI Scheme for promotion of domestic manufacturing of KSMs/ DIs and…
Production Linked Incentive Scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to…
Govt provides update on schemes implemented in the pharma sector
The PRIP scheme has been launched with an outlay of ₹ 5,000 crore to transform India’s Pharma MedTech sector
Biocon Biologics appoints Deepali Naair as head, corporate communications
Seema Ahuja will post her retirement from Biocon Biologics move into a non-business facing role in Biocon Chairperson’s office
Enhancing visibility, predictability and transparency in IP procedures
Milind Sathe, Vice President -IP and Tech, Themis Medicare, explains how certain robust search and tracking facilities can enhance…
Venus Foundation signs five-year MoU with Haryana Government
The initiative will drive targeted upgrades across physical, technological, and academic dimensions of school infrastructure, in…
FDA discontinue rare pediatric disease designation program despite increase in RPD approvals
Due to concerns over its effectiveness, the US Congress did not renew the RPDD program and began to close it in late 2024